Eloxx Pharmaceuticals, Inc. (ELOX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 31.78 Million USD | 39.67% |
| 2021 | 22.75 Million USD | 40.06% |
| 2020 | 16.24 Million USD | -28.53% |
| 2019 | 22.73 Million USD | 191.2% |
| 2018 | 7.8 Million USD | 128.07% |
| 2017 | 3.42 Million USD | -31.18% |
| 2016 | 4.97 Million USD | 6.62% |
| 2015 | 4.66 Million USD | -36.29% |
| 2014 | 7.32 Million USD | 25.28% |
| 2013 | 5.84 Million USD | 76.49% |
| 2012 | 3.31 Million USD | -5.43% |
| 2011 | 3.5 Million USD | -14.16% |
| 2010 | 4.07 Million USD | -31.22% |
| 2009 | 5.93 Million USD | 307.73% |
| 2008 | 1.45 Million USD | 80.18% |
| 2007 | 807.28 Thousand USD | 27.69% |
| 2006 | 632.2 Thousand USD | 8.37% |
| 2005 | 583.39 Thousand USD | 11.46% |
| 2004 | 523.39 Thousand USD | 9.01% |
| 2003 | 480.11 Thousand USD | 17.26% |
| 2002 | 409.44 Thousand USD | -7.89% |
| 2001 | 444.52 Thousand USD | -7.48% |
| 2000 | 480.46 Thousand USD | 113.25% |
| 1999 | 225.3 Thousand USD | 30.55% |
| 1998 | 172.58 Thousand USD | 5467.32% |
| 1997 | 3100.00 USD | -11.61% |
| 1996 | 3507.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 24.58 Million USD | 4.67% |
| 2023 Q1 | 23.49 Million USD | -26.08% |
| 2023 Q3 | 26.09 Million USD | 6.1% |
| 2022 Q2 | 31.12 Million USD | -2.51% |
| 2022 FY | 31.78 Million USD | 39.67% |
| 2022 Q4 | 31.78 Million USD | -0.24% |
| 2022 Q1 | 31.93 Million USD | 40.33% |
| 2022 Q3 | 31.86 Million USD | 2.35% |
| 2021 Q4 | 22.75 Million USD | 1.65% |
| 2021 Q1 | 17.61 Million USD | 8.43% |
| 2021 FY | 22.75 Million USD | 40.06% |
| 2021 Q2 | 19.96 Million USD | 13.35% |
| 2021 Q3 | 22.38 Million USD | 12.11% |
| 2020 Q4 | 16.24 Million USD | -9.05% |
| 2020 FY | 16.24 Million USD | -28.53% |
| 2020 Q1 | 20.78 Million USD | -8.58% |
| 2020 Q3 | 17.86 Million USD | -9.0% |
| 2020 Q2 | 19.63 Million USD | -5.55% |
| 2019 Q1 | 22.45 Million USD | 187.66% |
| 2019 FY | 22.73 Million USD | 191.2% |
| 2019 Q2 | 23.81 Million USD | 6.04% |
| 2019 Q3 | 22.82 Million USD | -4.14% |
| 2019 Q4 | 22.73 Million USD | -0.42% |
| 2018 Q1 | 5.65 Million USD | 0.0% |
| 2018 Q4 | 7.8 Million USD | 53.71% |
| 2018 Q2 | 4.44 Million USD | -21.31% |
| 2018 FY | 7.8 Million USD | 128.07% |
| 2018 Q3 | 5.07 Million USD | 14.21% |
| 2017 FY | 3.42 Million USD | -31.18% |
| 2017 Q2 | 4.97 Million USD | 52.69% |
| 2017 Q1 | 3.25 Million USD | 9.89% |
| 2017 Q3 | 3.27 Million USD | -34.13% |
| 2016 Q2 | 4.66 Million USD | -5.13% |
| 2016 FY | 4.97 Million USD | 6.62% |
| 2016 Q1 | 4.91 Million USD | -28.93% |
| 2016 Q3 | 3.38 Million USD | -27.4% |
| 2016 Q4 | 2.96 Million USD | -12.48% |
| 2015 Q3 | 6.93 Million USD | -5.3% |
| 2015 Q1 | 5.71 Million USD | -13.61% |
| 2015 Q4 | 6.91 Million USD | -0.22% |
| 2015 FY | 4.66 Million USD | -36.29% |
| 2015 Q2 | 7.32 Million USD | 28.16% |
| 2014 Q2 | 5.84 Million USD | 406.03% |
| 2014 Q3 | 5.7 Million USD | -2.36% |
| 2014 Q4 | 6.61 Million USD | 15.9% |
| 2014 FY | 7.32 Million USD | 25.28% |
| 2014 Q1 | 1.15 Million USD | -65.84% |
| 2013 Q2 | 3.31 Million USD | -7.5% |
| 2013 Q4 | 3.38 Million USD | -8.55% |
| 2013 FY | 5.84 Million USD | 76.49% |
| 2013 Q1 | 3.58 Million USD | -7.8% |
| 2013 Q3 | 3.69 Million USD | 11.65% |
| 2012 Q4 | 3.88 Million USD | 6.94% |
| 2012 FY | 3.31 Million USD | -5.43% |
| 2012 Q1 | 4.03 Million USD | 0.29% |
| 2012 Q2 | 3.5 Million USD | -13.23% |
| 2012 Q3 | 3.63 Million USD | 3.68% |
| 2011 Q3 | 4.33 Million USD | 6.35% |
| 2011 Q1 | 4.19 Million USD | -0.11% |
| 2011 Q4 | 4.02 Million USD | -7.25% |
| 2011 Q2 | 4.07 Million USD | -2.73% |
| 2011 FY | 3.5 Million USD | -14.16% |
| 2010 FY | 4.07 Million USD | -31.22% |
| 2010 Q1 | 5.8 Million USD | 134.34% |
| 2010 Q3 | 4.74 Million USD | -19.96% |
| 2010 Q2 | 5.93 Million USD | 2.23% |
| 2010 Q4 | 4.19 Million USD | -11.55% |
| 2009 Q3 | 2.43 Million USD | 67.14% |
| 2009 Q1 | 1.09 Million USD | 9.06% |
| 2009 Q4 | 2.47 Million USD | 1.83% |
| 2009 FY | 5.93 Million USD | 307.73% |
| 2009 Q2 | 1.45 Million USD | 33.13% |
| 2008 Q2 | 807.28 Thousand USD | -50.23% |
| 2008 FY | 1.45 Million USD | 80.18% |
| 2008 Q1 | 1.62 Million USD | 23.99% |
| 2008 Q4 | 1 Million USD | -0.61% |
| 2008 Q3 | 1 Million USD | 24.87% |
| 2007 Q2 | 632.2 Thousand USD | 32.34% |
| 2007 FY | 807.28 Thousand USD | 27.69% |
| 2007 Q3 | 961.61 Thousand USD | 52.1% |
| 2007 Q4 | 1.3 Million USD | 36.04% |
| 2007 Q1 | 477.7 Thousand USD | -10.3% |
| 2006 Q1 | 921.01 Thousand USD | 50.07% |
| 2006 FY | 632.2 Thousand USD | 8.37% |
| 2006 Q3 | 816.62 Thousand USD | 39.98% |
| 2006 Q2 | 583.39 Thousand USD | -36.66% |
| 2006 Q4 | 532.56 Thousand USD | -34.79% |
| 2005 FY | 583.39 Thousand USD | 11.46% |
| 2005 Q3 | 534.77 Thousand USD | 2.18% |
| 2005 Q2 | 523.39 Thousand USD | 17.95% |
| 2005 Q1 | 443.75 Thousand USD | -13.62% |
| 2005 Q4 | 613.71 Thousand USD | 14.76% |
| 2004 Q1 | 625.03 Thousand USD | 20.21% |
| 2004 Q2 | 480.11 Thousand USD | -23.19% |
| 2004 FY | 523.39 Thousand USD | 9.01% |
| 2004 Q3 | 487.49 Thousand USD | 1.54% |
| 2004 Q4 | 513.74 Thousand USD | 5.38% |
| 2003 Q2 | 409.44 Thousand USD | -20.93% |
| 2003 Q1 | 517.8 Thousand USD | 21.62% |
| 2003 Q4 | 519.96 Thousand USD | 5.15% |
| 2003 FY | 480.11 Thousand USD | 17.26% |
| 2003 Q3 | 494.51 Thousand USD | 20.78% |
| 2002 Q4 | 425.74 Thousand USD | -25.81% |
| 2002 FY | 409.44 Thousand USD | -7.89% |
| 2002 Q1 | 307.56 Thousand USD | -37.94% |
| 2002 Q2 | 444.52 Thousand USD | 44.53% |
| 2002 Q3 | 573.87 Thousand USD | 29.1% |
| 2001 Q3 | 894.21 Thousand USD | 86.12% |
| 2001 Q1 | 370.56 Thousand USD | 61.26% |
| 2001 FY | 444.52 Thousand USD | -7.48% |
| 2001 Q2 | 480.46 Thousand USD | 29.66% |
| 2001 Q4 | 495.61 Thousand USD | -44.58% |
| 2000 Q3 | 223.93 Thousand USD | -0.61% |
| 2000 FY | 480.46 Thousand USD | 113.25% |
| 2000 Q1 | 321.96 Thousand USD | 60.98% |
| 2000 Q2 | 225.3 Thousand USD | -30.02% |
| 2000 Q4 | 229.79 Thousand USD | 2.62% |
| 1999 Q4 | 200 Thousand USD | 0.0% |
| 1999 FY | 225.3 Thousand USD | 30.55% |
| 1998 FY | 172.58 Thousand USD | 5467.32% |
| 1997 FY | 3100.00 USD | -11.61% |
| 1996 FY | 3507.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -558.72% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1237.668% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 18.352% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 76.037% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1043.685% |
| Better Therapeutics, Inc. | 23.84 Million USD | -33.307% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -283.667% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -218.652% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -20.669% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 54.225% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -300.008% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 33.938% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 79.798% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -806.543% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -49.287% |
| Molecular Templates, Inc. | 31.17 Million USD | -1.963% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -153.961% |
| NexImmune, Inc. | 5.08 Million USD | -525.129% |
| Orgenesis Inc. | 35.53 Million USD | 10.559% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -92.484% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -11829.929% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1284.68% |
| Scopus BioPharma Inc. | 7.45 Million USD | -326.364% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 93.573% |
| Statera Biopharma, Inc. | 22.67 Million USD | -40.159% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -191.213% |
| Trevena, Inc. | 48.26 Million USD | 34.145% |
| Vaxxinity, Inc. | 30.94 Million USD | -2.711% |
| Vaccinex, Inc. | 5.94 Million USD | -434.887% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -1514.713% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 17.174% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1050.908% |